Search Within

Lorenzo Falchi

Formats
  1. Meeting Abstract (96)
  2. Journal Article (23)
  3. Research Letter (6)
  4. Review (5)
  5. Correspondence (2)
  6. Editorial (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (134)
  2. Hematologic Malignancies, Division of (134)
  3. Center for Hematologic Malignancies (88)
  4. Lymphoma (78)
  5. Sloan Kettering Institute Postdocs (57)
  6. Survivorship Research (54)

More Groups

People
  1. Gilles Salles (66)
  2. Andrew Zelenetz (64)
  3. Maria Palomba (63)
  4. Anita Kumar (61)
  5. Ariela Noy (57)
  6. Alison Moskowitz (54)

More People

Years
  1. 2025 (8)
  2. 2024 (40)
  3. 2023 (43)
  4. 2022 (23)
  5. 2021 (14)
  6. 2020 (6)
Publications
  1. Blood (67)
  2. Journal of Clinical Oncology (11)
  3. Hematological Oncology (9)
  4. Blood Advances (5)
  5. Clinical Lymphoma, Myeloma and Leukemia (5)
  6. Leukemia and Lymphoma (5)

More Publications

Publishers
  1. American Society of Hematology (72)
  2. American Society of Clinical Oncology (11)
  3. Wiley Blackwell (9)
  4. Elsevier Inc. (8)
  5. Taylor & Francis Group (5)
  6. Ferrata Storti Foundation (4)

More Publishers

Results (134)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis
    Research Letter

    Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Pak, T.; Chang, T.; Dao, P.; Moskowitz, A. J.; Stuver, R. N.; Ghione, P.; Galasso, N.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Epcoritamab with rituximab + lenalidomide (R(2)) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7
    Meeting Abstract

    Lori, L. A.; Falchi, L.; Vermaat, J. S. P.; Musuraca, G.; Belada, D.; Nijland, M.; Christensen, J. H.; Offner, F.; Hoehn, D.; Marek, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Karimi, Y.; Abrisqueta, P.; de Vos, S.; Nijland, M.; Offner, F.; Osei-Bonsu, K.; Rana, A.; Archer, K. G.; Song, Y.; Cordoba, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501, a first-in-class NK cell engager, in patients with relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma
    Meeting Abstract

    Falchi, L.; Walker, P.; Presgrave, P.; Gregory, G. P.; Marie, D.; Leyco, A. J.; Demaria, O.; Le Floch, F.; Hanekom, W.; Bonin, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
    Guidelines

    Crombie, J. L.; Graff, T.; Falchi, L.; Karimi, Y. H.; Bannerji, R.; Nastoupil, L.; Thieblemont, C.; Ursu, R.; Bartlett, N.; Nachar, V.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Trial watch: Bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma
    Review

    Cassanello, G.; Luna de Abia, A.; Falchi, L.
    OncoImmunology (2024)

    Fulltext@MSK | Save
  • The use of glofitamab in relapsed diffuse large B-cell lymphoma
    Review

    Falchi, L.
    Clinical Advances in Hematology & Oncology (2024)

    Fulltext@MSK | Save
  • Diffuse large B-cell lymphoma involving osseous sites: Utility of response assessment by PET/CT and good long-term outcomes
    Journal Article

    Ghione, P.; Ahsanuddin, S.; Luttwak, E.; Varela, S. B.; Nakajima, R.; Michaud, L.; Gupta, K.; Navitski, A.; Straus, D.; Palomba, M. L.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Dexamethasone is associated with a lower incidence and severity of cytokine release syndrome compared with other corticosteroid regimens when given as premedication for glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)
    Meeting Abstract

    Falchi, L.; Carlo-Stella, C.; Morschhauser, F.; Dickinson, M.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • EPCORE FL-1: Phase 3 trial of subcutaneous epcoritamab with rituximab and lenalidomide (R (2)) Vs R (2) alone in patients with relapsed or refractory follicular lymphoma
    Meeting Abstract

    Falchi, L.; Morschhauser, F.; Linton, K.; Huang, H.; Galderisi, F.; Quadri, S.; Zeng, L.; Hoehn, D.; Seymour, J. F.
    Blood (2023)

    Fulltext@MSK | Save